Os therapies announces last patient enrolled in ost-her2 osteosarcoma phase 2b clinical trial receives last treatment dose

New york--(business wire)--os therapies incorporated (nyse american: ostx) (“os therapies” or “the company”), an adc and immunotherapy research and clinical-stage biopharmaceutical company, today announced that the last patient (patient #41) enrolled in the aost-2121 clinical trial (nct04974008) of ost-her2 in recurred, resected osteosarcoma (os) - has received its last treatment dose. this last patient is expected to complete its final radiological imaging evaluation as part of the 12-month ev.
OST Ratings Summary
OST Quant Ranking